English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/200183
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorPineda, Juan A.-
dc.contributor.authorMorano-Amado, Luis E.-
dc.contributor.authorGranados, Rafael-
dc.contributor.authorMacias, Juan-
dc.contributor.authorTéllez, Francisco-
dc.contributor.authorGarcía-Deltoro, Miguel-
dc.contributor.authorRíos-Villegas, María José-
dc.contributor.authorCollado, Antonio-
dc.contributor.authorDelgado-Fernández, Marcial-
dc.contributor.authorSuárez-Santamaría, M.-
dc.contributor.authorSerrano, Manuel-
dc.contributor.authorMiralles-Álvarez, C.-
dc.contributor.authorNeukam, Karin-
dc.identifierdoi: 10.1016/j.cmi.2016.12.034-
dc.identifiere-issn: 1469-0691-
dc.identifierissn: 1198-743X-
dc.identifier.citationClinical Microbiology and Infection 23(6): 409.e5-409.e8 (2017)-
dc.descriptionGrupo de Estudio de Hepatitis Vírica, of the Sociedad Andaluza de Enfermedades Infecciosas y Microbiología Clínica: HEPAVIR / Red de Investigación en SIDA (RIS-HEP07); J. C. Alados-Arboledas, H. Albendín, M. R. Alemán, M. del Mar Alonso, V. Asensi, M. J. Blanco, J. Borrallo, R. Cabo, Á. Camacho, M. F. Casas, Á. Castro, J. Cucurull, S. Cuéllar, F. CuencaI.de los Santos-Gil, C. Dueñas, E. Fernández, C. Galera, M. C. Gálvez, D. García, P. Geijo-Martínez, A. Gómez, J. L. Gómez, F. Gutiérrez, J. Hernández, J. Hernández, J. Llenas-García, M. Mancebo, M. Márquez, J. M. Martín, L. Martínez, R. Martínez-Álvarez, O. Martínez Madrid, M. del Mar Masiá, N. Merchante, D. Merino, P. Monje, R. Nuñez, M. Omar, E. Ortega, S. Padilla, C. Robledano, R. Pelazas, E. Pérez, I. Pérez-Camacho, M. Pérez-Pérez, B. Pernas, J. J. Portu, M. Raffo, L. M. Real, G. Reina, A. Rivero, A. Rivero-Juárez, A. Romero-Palacios, J. Portilla, P. Rubio, P. Ryan-Murua, P. S.de la Hoya, J.Santos, M. Serrano, C. Toyas, F. Vera-Méndez, A. Vergara, M. V. Hernández, D. V. García.-
dc.description.abstract[Objective] The aim of this study was to determine the predictive capacity of response at treatment week (TW) 4 for the achievement of sustained virological response 12 weeks after the scheduled end of therapy date (SVR12) to treatment against hepatitis C virus (HCV) genotype 3 (GT3) infection with all-oral direct-acting antiviral (DAA) -based regimens.-
dc.description.abstract[Patients and methods] From a prospective multicohort study, HCV GT3-infected patients who completed a course of currently recommended DAA-based therapy at 33 Spanish hospitals and who had reached the SVR12 evaluation time-point were selected. TW4 HCV-RNA levels were categorized as target-not-detected (TND), below the lower limit of quantification (LLOQTD) and ≥LLOQ.-
dc.description.abstract[Results] A total of 123 patients were included, 86 (70%) received sofosbuvir/ daclatasvir ± ribavirin, 27 (22%) received sofosbuvir/ ledipasvir/ ribavirin and 10 (8.1%) received sofosbuvir/ ribavirin, respectively. In all, 114 (92.7%) of the 123 patients presented SVR12 in an on-treatment approach, but nine (7.3%) patients relapsed, all of them had presented cirrhosis at baseline. In those who achieved TND, LLOQTD and ≥LLOQ, SVR12 was observed in 81/83 (98%; 95% CI 91.5%–99.7%), 24/28 (85.7%; 95% CI 67.3%–96%) and 9/12 (75%; 95% CI 42.8%–94.5%), respectively; p(linear association) 0.001. Corresponding numbers for subjects with cirrhosis were: 52/54 (96.3%; 95% CI 87.3%–95.5%), 14/18 (77.8%; 95% CI 52.4%–93.6%) and 7/10 (70%; 95% CI 34.8%–93.3%); p 0.004.-
dc.description.abstract[Conclusions] TW4-response indicates the probability of achieving SVR12 to currently used DAA-based therapy in HCV genotype 3-infected individuals with cirrhosis. This finding may be useful to tailor treatment strategy in this setting.-
dc.description.sponsorshipThis work has been partially funded by the RD12/0017/0012 project as part of the Plan Nacional R+D+I and co-financed by ISCIII-Subdirección General de Evaluación, the Fondo Europeo de Desarrollo Regional (FEDER) and the Consejería de Salud of the Junta de Andalucía (grant number AC-0095-2013 and PI-0492-2012). JAP is the recipient of an intensification grant from the Instituto de Salud Carlos III (grant number Programa-I3SNS). JM is the recipient of a grant from the Servicio Andaluz de Salud of the Junta de Andalucía (grant number B-0037). KN is the recipient of a Miguel Servet research grant from the Instituto de Salud Carlos III (grant number CP13/00187).-
dc.subjectDirect-acting antivirals-
dc.subjectHepatitis C virus genotype 3-
dc.subjectInterferon-free regimens-
dc.subjectSustained virological response-
dc.subjectViral kinetics-
dc.titleWeek 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection-
dc.contributor.funderInstituto de Salud Carlos III-
dc.contributor.funderEuropean Commission-
dc.contributor.funderJunta de Andalucía-
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show simple item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.